Orna Therapeutics

Exciting opportunity in East Cambridge! Please see details below for a newly constructed, intensive chemistry space at 640 Memorial Drive.    - Sublease from Orna Tx following their acquisition of ReNAgade - Space ranging from 17,000 to 50,000 RSF for immediate occupancy  - Lease term through until August 2027 - Space includes custom built chemistry lab suitable for RNA and / or lipid synthesis including walk-in hoods - Flexibility to sub-divide space based on needs - High quality building amenities including brand new gym   For more information, visit the provided link or contact Tucker Hansen or Anslee Krouch directly.   https://bit.ly/4guJjXV   #EastCambridge #ChemistrySpace #StateOfTheArt

We’re pleased to welcome Vikas Sinha to our Board of Directors. With more than 25 years of experience in financial roles in the life sciences industry, Mr. Sinha’s expertise will be crucial as we enter our next stage of growth and advance our panCAR™ programs for patients with cancer and autoimmune diseases. #RNA #Biotech #BioPharma   Read more here: https://lnkd.in/euZi7-J2

We’re thrilled to announce our three-year strategic research collaboration with Vertex Pharmaceuticals. This partnership will enable Orna to utilize our novel and proprietary lipid nanoparticle delivery solutions to enhance Vertex’s efforts in developing next generation gene editing therapies for patients with sickle cell disease and dependent beta thalassemia.   Read more here: https://lnkd.in/eM6xqv4f

Congratulations to Orna's sixteen Fall 2024 co-op participants! Last night, they showcased their incredible work at our capstone Poster Night. A big thank you to each of them for their outstanding contributions to advancing Orna's mission. #BioTech #BioPharma

Yesterday, at the 66th American Society of Hematology (ASH) Annual Meeting, we presented a poster highlighting new preclinical data demonstrating the potential of our in vivo panCAR™ platform for the treatment of B cell mediated diseases. #ASH24 #celltherapy   Read more here: https://lnkd.in/evzSvzVB

  Join us this Wednesday, December 4th, at the 2nd Annual Cell Therapy for Autoimmune Diseases Summit. Our Head of Discovery, Isin Dalkilic-Liddle, PhD, will be presenting the latest research leveraging our Circle RNA technology to unlock the next generation of in vivo panCAR therapies for the treatment of autoimmune disease. #celltherapy #automimmunedisease

Viva Roma! Heading to the 31st Annual European Society of Gene and Cell Therapy Congress? Come check out Poster Session 1, where Dan Egan, PhD Director, Gene Editing, will present research on Orna’s in vivo hematopoietic stem cell gene editing approach for the treatment of beta-hemoglobinopathies. Join us to learn more about how we’re pioneering the next chapter of safe and effective in vivo therapies with leading circular RNA (oRNA®) and unprecedented lipid nanoparticle (LNP) delivery solutions. https://lnkd.in/e_FEnzpu #ESGCT2024 #GeneTherapy #GeneEditing #Biotech

We believe in fueling curiosity, creativity and innovation, and are proud to contribute to building a brighter, equitable future for girls in science. Recently Orna had the pleasure of collaborating with Science Club for Girls to support the next generation of female scientists by donating laptops. These devices will empower young minds through the Club’s free experiential programs in the Greater Boston area, providing tools and hands-on learning opportunities to explore STEM, ignite confidence, and connect with women-in-STEM mentors to foster their scientific interests and academic goals. Take a moment to learn more here about Science Club for Girls and its impact. https://lnkd.in/eE8Vj2wB #DiversityInSTEM #WomenInSTEM #GirlsInSTEM

This Thursday, September 19th, Orna CSO Robert Mabry will be speaking at the 9th Annual CAR-TCR Summit Series. Join us as we present the latest data on circular RNA therapy for the treatment of B cell malignancies, and participate in a panel discussion highlighting the potential for the next generation of in vivo #celltherapy. #CARTCR2024

We’re thrilled to welcome Nobel Laureate Carolyn Bertozzi to our Scientific Advisory Board as Co-Chair alongside Tom Barnes. Dr. Bertozzi’s expertise as a pioneer in emerging technologies will be invaluable as we advance a new category of panCAR™ in vivo CAR RNA medicines. We look forward to working with Drs. Bertozzi and Barnes to realize the full potential of RNA therapeutics for cancer and autoimmune diseases.   Read more here: https://lnkd.in/eMbF9Y4V #RNA #Biotech #BioPharma #Science